Companies Scholar Rock Holding Corp
Scholar Rock (SRRK): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Scholar Rock Holding Corp’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers99th pct.Of 21 peer CEOs
CEO pay, last three years
- $33,300,927FY2025
CEO total pay was $33,300,927 in fiscal 2025; the brief holds no earlier figure for this CEO.
FY2025: salary $637,500 · bonus $2,000,000 · stock awards $22,518,500 · option awards $7,624,988
Executives and directors
Akshay Vaishnaw · PresidentDavid Hallal · CEOR. Keith Woods · COOJay Backstrom · CEOVikas Sinha · CFOJay Backstrom, M.D., M.P.H · Former director (through FY2025)Jeffrey S. Flier, M.D · Independent DirectorJoshua Reed · Independent DirectorKatie Peng · Independent DirectorKristina Burow · Independent DirectorMichael Gilman, Ph.D · Independent DirectorRichard Brudnick · Independent DirectorSrinivas Akkaraju, M.D., Ph.D · Independent Director
Frequently asked questions
Who was the highest-paid executive at Scholar Rock Holding Corp in fiscal 2025?
As disclosed, David Hallal (Chief Executive Officer and Chairman) was the highest-paid executive at Scholar Rock Holding Corp in fiscal 2025, with total compensation of $33,300,927.
How does Scholar Rock Holding Corp's chief executive pay compare to its disclosed peer group?
As disclosed, David Hallal's total compensation ranked at the 99th percentile of Scholar Rock Holding Corp's disclosed peer group.
How did shareholders vote on Scholar Rock Holding Corp's executive compensation?
As disclosed, 61.66% of shareholders supported Scholar Rock Holding Corp's executive compensation in the latest say-on-pay vote.
How much does Scholar Rock Holding Corp spend in total on board compensation for fiscal 2025?
As disclosed, Scholar Rock Holding Corp reported total board compensation of $2,097,148 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| David Hallal | $637,500 | $2,000,000 | $22,518,500 | $7,624,988 | $452,293 | $0 | $67,646 | $33,300,927 |
| Chief Executive Officer and Chairman | ||||||||
| Jay Backstrom | 600,231 | 0 | 5,895,227 | 9,848,049 | 0 | 0 | 1,145,317 | 17,488,824 |
| Former President and Chief Executive Officer | ||||||||
| Akshay Vaishnaw | 523,077 | 2,000,000 | 9,007,400 | 3,050,001 | 278,334 | 0 | 32,555 | 14,891,367 |
| President of R&D | ||||||||
| R. Keith Woods | 523,077 | 0 | 9,007,400 | 3,050,001 | 278,334 | 0 | 57,187 | 12,915,999 |
| Chief Operating Officer | ||||||||
| Vikas Sinha | 523,077 | 0 | 9,007,400 | 3,050,001 | 278,334 | 0 | 14,036 | 12,872,848 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| David Hallal | $33,300,927 | — | — | — |
| Jay Backstrom | 17,488,824 | 7,991,933 | 4,111,853 | ↑ +9,496,891 |
| Akshay Vaishnaw | 14,891,367 | — | — | — |
| R. Keith Woods | 12,915,999 | — | — | — |
| Vikas Sinha | 12,872,848 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program consists of a combination of base salary, non-equity incentive compensation, and long-term equity incentives. The program is structured based on consideration of compensation levels for comparable positions at peer companies, historical compensation levels for individual executives, individual executive performance, criticality of role, achievement of corporate objectives, and other relevant considerations.
| CEO STI target (% of salary) | 80% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| R. Keith Woods | Option | — | — | — | — | — | $3,050,001 |
| David Hallal | PRSU | — | — | — | — | — | 22,518,500 |
| R. Keith Woods | PRSU | — | — | — | — | — | 9,007,400 |
| Jay Backstrom | Option | — | — | — | — | — | 9,848,049 |
| Akshay Vaishnaw | Option | — | — | — | — | — | 3,050,001 |
| Jay Backstrom | PRSU | — | — | — | — | — | 5,895,227 |
| Vikas Sinha | PRSU | — | — | — | — | — | 9,007,400 |
| David Hallal | Option | — | — | — | — | — | 7,624,988 |
| Akshay Vaishnaw | PRSU | — | — | — | — | — | 9,007,400 |
| Vikas Sinha | Option | — | — | — | — | — | 3,050,001 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| R. Keith Woods | $0 | $0 | $3,050,001 | 0.0% |
| David Hallal | 0 | 0 | 7,624,988 | 0.0% |
| Jay Backstrom | 0 | 0 | 9,848,049 | 0.0% |
| Akshay Vaishnaw | 0 | 0 | 3,050,001 | 0.0% |
| Vikas Sinha | 0 | 0 | 3,050,001 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Akshay Vaishnaw | RSU | 100,000 | — | $4,405,000 |
| R. Keith Woods | RSU | 100,000 | — | 4,405,000 |
| Vikas Sinha | RSU | 100,000 | — | 4,405,000 |
| Akshay Vaishnaw | Option | 110,067 | 27.71 | — |
| Vikas Sinha | Option | 110,067 | 27.71 | — |
| Akshay Vaishnaw | Option | 110,067 | 32.91 | — |
| Vikas Sinha | Option | 110,067 | 32.91 | — |
| R. Keith Woods | Option | 110,067 | 32.91 | — |
| David Hallal | RSU | 250,000 | — | 11,012,500 |
| David Hallal | Option | 275,167 | 27.71 | — |
| David Hallal | Option | 275,167 | 32.91 | — |
| Akshay Vaishnaw | PSU | 500,000 | — | 22,025,000 |
| Vikas Sinha | PSU | 500,000 | — | 22,025,000 |
| David Hallal | PSU | 1,250,000 | — | 55,062,500 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jeffrey S. Flier, M.DIndependent · Nominating and Corporate Governance (Chair) · Science, Innovation and Technology (Chair) · Not standing for re-election | $75,712 | $232,471 | $232,479 | — | $0 | $540,662 |
| Joshua ReedIndependent · Audit (Chair) · Nominating and Corporate Governance · Not standing for re-election | 75,102 | 232,471 | 232,479 | — | 0 | 540,052 |
| Katie PengIndependent · Audit · Compensation | 66,188 | 232,471 | 232,479 | — | 0 | 531,138 |
| Kristina BurowIndependent · Compensation (Chair) | 66,099 | 232,471 | 232,479 | — | 0 | 531,049 |
| Michael Gilman, Ph.DIndependent · Compensation · Science, Innovation and Technology | 66,099 | 232,471 | 232,479 | — | 0 | 531,049 |
| Srinivas Akkaraju, M.D., Ph.DIndependent · Nominating and Corporate Governance · Science, Innovation and Technology · Not standing for re-election | 61,077 | 232,471 | 232,479 | — | 0 | 526,027 |
| Richard BrudnickIndependent · Audit · Not standing for re-election | 59,574 | 232,471 | 232,479 | — | 0 | 524,524 |
| Akshay Vaishnaw, M.D., Ph.DEmployee director · Not standing for re-election | 0 | 0 | 0 | — | 0 | 0 |
| David HallalEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Jay Backstrom, M.D., M.P.HEmployee director · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $465,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 12,500 / 10,000 / 6,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $469,851 |
| Equity awards (grant-date value) | $1,627,297 |
| All other compensation | $0 |
| Total cost of the board | $2,097,148 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Scholar Rock as a peer
Companies that benchmark against SRRK
7 companies name SRRK as a compensation peer
The list of companies that name SRRK as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
DNLI Denali Therapeutics Inc.RCKT Rocket Pharmaceuticals, Inc.AGIO Agios Pharmaceuticals, Inc.APLS Apellis Pharmaceuticals, Inc.RCUS Arcus Biosciences, Inc.ARWR Arrowhead Pharmaceuticals, Inc.RNAM Avidity Biosciences, Inc.BHVN Biohaven Ltd.BPMC Blueprint Medicines CorporationDYN Dyne Therapeutics, Inc.MDGL Madrigal Pharmaceuticals, Inc.PTCT PTC Therapeutics, Inc.RYTM Rhythm Pharmaceuticals, Inc.SWTX SpringWorks Therapeutics, Inc.SNDX Syndax Pharmaceuticals, Inc.RARE Ultragenyx Pharmaceutical Inc.CRNX Crinetics Pharmaceuticals, Inc.BBIO BridgeBio Pharma, Inc.AXSM Axsome Therapeutics, Inc.VRDN Viridian Therapeutics, Inc.DAWN Day One Biopharmaceuticals, Inc.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Scholar Rock Holding Corp | 2025 | David Hallal | $637,500 | $22,518,500 | $7,624,988 | $452,293 | $33,300,927 |
| 2 | PTC Therapeutics, Inc. | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 3 | Madrigal Pharmaceuticals, Inc. | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 4 | Rhythm Pharmaceuticals, Inc. | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 5 | SpringWorks Therapeutics, Inc. | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 6 | BridgeBio Pharma, Inc. | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 7 | Avidity Biosciences, Inc. | 2024 | Sarah Boyce | 659,900 | 10,748,480 | 2,157,090 | 594,000 | 14,176,480 |
| 8 | Biohaven Ltd. | 2025 | Vlad Coric | 920,400 | 2,202,480 | 9,900,043 | 0 | 13,500,438 |
| 9 | Blueprint Medicines Corporation | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 10 | Crinetics Pharmaceuticals, Inc. | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 11 | Ultragenyx Pharmaceutical Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 12 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 13 | Axsome Therapeutics, Inc. | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 14 | Arcus Biosciences, Inc. | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 15 | Arrowhead Pharmaceuticals, Inc. | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 16 | Syndax Pharmaceuticals, Inc. | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 17 | Viridian Therapeutics, Inc. | 2025 | Stephen Mahoney | 700,000 | 1,058,098 | 4,381,713 | 630,000 | 6,776,249 |
| 18 | Day One Biopharmaceuticals, Inc. | 2024 | Jeremy Bender | 680,000 | 2,700,280 | 2,664,697 | 501,800 | 6,560,577 |
| 19 | Agios Pharmaceuticals, Inc. | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 20 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 21 | Rocket Pharmaceuticals, Inc. | 2025 | Gaurav Shah | 671,076 | 806,751 | 1,613,377 | 403,048 | 3,510,241 |
| 22 | Dyne Therapeutics, Inc. | 2025 | John Cox | 721,000 | 0 | 937,893 | 410,970 | 2,076,868 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Scholar Rock Holding Corp | not disclosed | not disclosed | No | Pay Governance |
| Agios Pharmaceuticals, Inc. | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Arcus Biosciences, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Arrowhead Pharmaceuticals, Inc. | 125% | PRSU 70 · RSU 30 | not disclosed | Compensia |
| Avidity Biosciences, Inc. | not disclosed | Option 80 · RSU 20 | not disclosed | Alpine Rewards, LLC |
| Axsome Therapeutics, Inc. | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Biohaven Ltd. | not disclosed | not disclosed | not disclosed | Aon |
| Blueprint Medicines Corporation | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| BridgeBio Pharma, Inc. | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Crinetics Pharmaceuticals, Inc. | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Day One Biopharmaceuticals, Inc. | 123%% | Stock Options 50 · RSUs 50 | not disclosed | Compensia Inc. |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Dyne Therapeutics, Inc. | 95% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Madrigal Pharmaceuticals, Inc. | not disclosed | PSU 33.33 · RSU 33.33 · Option 33.33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia, Inc. |
| PTC Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Rhythm Pharmaceuticals, Inc. | 120% | Options 50 · RSU 50 | No | Pay Governance |
| Rocket Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Semler Brossy |
| SpringWorks Therapeutics, Inc. | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon |
| Syndax Pharmaceuticals, Inc. | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Ultragenyx Pharmaceutical Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| Viridian Therapeutics, Inc. | 150% | Options 75 · RSU 25 | not disclosed | Compensia |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 68,280,961 | 42,455,921 | 131,015 | 61.66% | Passed |
| 2025 | 2025-05-22 | 84,838,269 | 3,279,486 | 37,887 | 96.28% | Passed |
| 2024 | 2024-06-27 | 69,061,313 | 1,773,153 | 108,401 | 97.5% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-04 | 61.66%a |
| 2025 | 2025-05-22 | 96.28%b |
| 2024 | 2024-06-27 | 97.5%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will have no effect on the outcome of the vote on this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will have no effect on the outcome of the vote on this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will have no effect on the outcome of the vote on this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Kristina Burow | Director | 2026-04-23 | A | 18,000 | $8 | $150,480 | Common | Form 4 ↗ |
| Kristina Burow | Director | 2026-04-23 | A | 28,000 | 5 | 133,000 | Common | Form 4 ↗ |
| Kristina Burow | Director | 2026-04-23 | D | 18,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kristina Burow | Director | 2026-04-23 | D | 36,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kristina Burow | Director | 2026-04-23 | D | 28,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kristina Burow | Director | 2026-04-23 | D | 7,800 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kristina Burow | Director | 2026-04-23 | A | 36,000 | 9 | 327,960 | Common | Form 4 ↗ |
| Kristina Burow | Director | 2026-04-23 | A | 7,800 | 27 | 208,884 | Common | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2026-06-04 | A | 6,839 | 0 | 0 | Common | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2026-06-04 | A | 4,310 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katie Peng | Director | 2026-06-04 | A | 6,839 | 0 | 0 | Common | Form 4 ↗ |
| Katie Peng | Director | 2026-06-04 | A | 4,310 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Gilman | Director | 2026-06-04 | A | 6,839 | 0 | 0 | Common | Form 4 ↗ |
| Kristina Burow | Director | 2026-06-04 | A | 6,839 | 0 | 0 | Common | Form 4 ↗ |
| Richard Brudnick | Director | 2026-06-04 | A | 4,310 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joshua Reed | Director | 2026-06-04 | A | 6,839 | 0 | 0 | Common | Form 4 ↗ |
| Joshua Reed | Director | 2026-06-04 | A | 4,310 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey S. Flier | Director | 2026-06-04 | A | 6,839 | 0 | 0 | Common | Form 4 ↗ |
| Michael Gilman | Director | 2026-06-04 | A | 4,310 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kristina Burow | Director | 2026-06-04 | A | 4,310 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey S. Flier | Director | 2026-06-04 | A | 4,310 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Brudnick | Director | 2026-06-04 | A | 6,839 | 0 | 0 | Common | Form 4 ↗ |
| Jeffrey S. Flier | Director | 2026-07-01 | D | 15 | 55 | 823 | Common | Form 4 ↗ |
| Jeffrey S. Flier | Director | 2026-07-01 | D | 1,470 | 54 | 79,728 | Common | Form 4 ↗ |
| Jeffrey S. Flier | Director | 2026-07-01 | D | 1,568 | 54 | 83,939 | Common | Form 4 ↗ |
| Michael Gilman | Director | 2026-07-01 | D | 1,346 | 54 | 72,070 | Common | Form 4 ↗ |
| Katie Peng | Director | 2026-07-01 | D | 21 | 55 | 1,154 | Common | Form 4 ↗ |
| Katie Peng | Director | 2026-07-01 | D | 2,437 | 54 | 132,214 | Common | Form 4 ↗ |
| Katie Peng | Director | 2026-07-01 | D | 2,988 | 54 | 160,037 | Common | Form 4 ↗ |
| Joshua Reed | Director | 2026-07-01 | D | 948 | 54 | 51,459 | Common | Form 4 ↗ |
| Joshua Reed | Director | 2026-07-01 | D | 2,105 | 53 | 112,609 | Common | Form 4 ↗ |
| Kristina Burow | Director | 2026-07-01 | D | 948 | 54 | 51,459 | Common | Form 4 ↗ |
| Kristina Burow | Director | 2026-07-01 | D | 2,105 | 53 | 112,605 | Common | Form 4 ↗ |
| Michael Gilman | Director | 2026-07-01 | D | 43 | 55 | 2,357 | Common | Form 4 ↗ |
| Michael Gilman | Director | 2026-07-01 | D | 1,155 | 54 | 62,631 | Common | Form 4 ↗ |
| David Hallal | Director | 2026-09-21 | D | 36,652 | 0 | 0 | Common, indirect | Form 4 ↗ |
| R. Keith Woods | Chief Operating Officer | 2026-09-24 | D | 48,034 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2026-10-23 | A | 1,000 | 42 | 41,820 | Common, indirect | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2026-10-23 | A | 500 | 42 | 20,910 | Common, indirect | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2026-10-23 | A | 94,000 | 41 | 3,883,140 | Common, indirect | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2026-10-23 | A | 47,000 | 41 | 1,941,570 | Common, indirect | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2026-10-26 | A | 97,982 | 42 | 4,075,071 | Common, indirect | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2026-10-26 | A | 48,988 | 42 | 2,037,411 | Common, indirect | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (97 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, David Hallal. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table for Fiscal 2025” · page 25. As printed: 33,300,927. View filing ↗
- Section 01, Jay Backstrom. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table for Fiscal 2025”. As printed: 17,488,824. View filing ↗
- Section 01, Akshay Vaishnaw. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table for Fiscal 2025”. As printed: 14,891,367. View filing ↗
- Section 01, R. Keith Woods. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table for Fiscal 2025”. As printed: 12,915,999. View filing ↗
- Section 01, Vikas Sinha. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table for Fiscal 2025”. As printed: 12,872,848. View filing ↗
- Section 03, R. Keith Woods Option. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, David Hallal PRSU. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, R. Keith Woods PRSU. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Jay Backstrom Option. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Akshay Vaishnaw Option. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Jay Backstrom PRSU. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Vikas Sinha PRSU. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, David Hallal Option. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Akshay Vaishnaw PRSU. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Vikas Sinha Option. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-03. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Jeffrey S. Flier, M.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 540,662. View filing ↗
- Section 08, Joshua Reed. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 540,052. View filing ↗
- Section 08, Katie Peng. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 531,138. View filing ↗
- Section 08, Kristina Burow. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 531,049. View filing ↗
- Section 08, Michael Gilman, Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 531,049. View filing ↗
- Section 08, Srinivas Akkaraju, M.D., Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 526,027. View filing ↗
- Section 08, Richard Brudnick. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 524,524. View filing ↗
- Section 08, Akshay Vaishnaw, M.D., Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, David Hallal. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Jay Backstrom, M.D., M.P.H. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Kristina Burow 2026-04-23. Form 4, filed 2026-04-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristina Burow 2026-04-23. Form 4, filed 2026-04-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristina Burow 2026-04-23. Form 4, filed 2026-04-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristina Burow 2026-04-23. Form 4, filed 2026-04-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristina Burow 2026-04-23. Form 4, filed 2026-04-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristina Burow 2026-04-23. Form 4, filed 2026-04-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristina Burow 2026-04-23. Form 4, filed 2026-04-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristina Burow 2026-04-23. Form 4, filed 2026-04-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katie Peng 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katie Peng 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Gilman 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristina Burow 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Brudnick 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joshua Reed 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joshua Reed 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey S. Flier 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Gilman 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristina Burow 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey S. Flier 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Brudnick 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey S. Flier 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey S. Flier 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey S. Flier 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Gilman 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katie Peng 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katie Peng 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katie Peng 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joshua Reed 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joshua Reed 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristina Burow 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristina Burow 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Gilman 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Gilman 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Hallal 2026-09-21. Form 4, filed 2026-09-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, R. Keith Woods 2026-09-24. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2026-10-23. Form 4, filed 2026-10-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2026-10-23. Form 4, filed 2026-10-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2026-10-23. Form 4, filed 2026-10-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2026-10-23. Form 4, filed 2026-10-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2026-10-26. Form 4, filed 2026-10-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2026-10-26. Form 4, filed 2026-10-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-05. Item 5.07 · say-on-pay result. As reported: 61.66% (votes for as printed: 68,280,961). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-23. Item 5.07 · say-on-pay result. As reported: 96.28% (votes for as printed: 84,838,269). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-28. Item 5.07 · say-on-pay result. As reported: 97.5% (votes for as printed: 69,061,313). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 469,851 + equity 1,627,297 + all other 0 = 2,097,148, summed across the director compensation table rows.
- Scholar Rock Holding Corp (subject), Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Scholar Rock Holding Corp's own proxy. As printed: 33,300,927. View filing ↗
- PTC Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. View filing ↗
- Madrigal Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Madrigal Pharmaceuticals, Inc.'s own proxy. As printed: 19,206,341. View filing ↗
- Rhythm Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. View filing ↗
- SpringWorks Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-04. CEO total compensation as printed in SpringWorks Therapeutics, Inc.'s own proxy. As printed: 16,153,317. View filing ↗
- BridgeBio Pharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. View filing ↗
- Avidity Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Avidity Biosciences, Inc.'s own proxy. As printed: 14,176,480. View filing ↗
- Biohaven Ltd., Section 10b CEO total. DEF 14A, filed 2026-03-13. CEO total compensation as printed in Biohaven Ltd.'s own proxy. As printed: 13,500,438. View filing ↗
- Blueprint Medicines Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. View filing ↗
- Crinetics Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Crinetics Pharmaceuticals, Inc.'s own proxy. As printed: 11,628,959. View filing ↗
- Ultragenyx Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. View filing ↗
- Apellis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. View filing ↗
- Axsome Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. View filing ↗
- Arcus Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. View filing ↗
- Arrowhead Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-01-27. CEO total compensation as printed in Arrowhead Pharmaceuticals, Inc.'s own proxy. As printed: 9,029,861. View filing ↗
- Syndax Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals, Inc.'s own proxy. As printed: 7,089,213. View filing ↗
- Viridian Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Viridian Therapeutics, Inc.'s own proxy. As printed: 6,776,249. View filing ↗
- Day One Biopharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-11. CEO total compensation as printed in Day One Biopharmaceuticals, Inc.'s own proxy. As printed: 6,560,577. View filing ↗
- Agios Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. View filing ↗
- Denali Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. View filing ↗
- Rocket Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Rocket Pharmaceuticals, Inc.'s own proxy. As printed: 3,510,241. View filing ↗
- Dyne Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Dyne Therapeutics, Inc.'s own proxy. As printed: 2,076,868. View filing ↗